The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial

CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen receptor positive breast cancer. Mechanisms of CDK4/6 inhibitor resistance have been described pre-clinically, with limited evidence from clinical samples. We conducted paired baseline and end of treatment circu...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Discov
Asıl Yazarlar: O’Leary, Ben, Cutts, Rosalind J, Liu, Yuan, Hrebien, Sarah, Huang, Xin, Fenwick, Kerry, André, Fabrice, Loibl, Sibylle, Loi, Sherene, Garcia-Murillas, Isaac, Cristofanilli, Massimo, Huang Bartlett, Cynthia, Turner, Nicholas C
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6368247/
https://ncbi.nlm.nih.gov/pubmed/30206110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-18-0264
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller